3D, whose subsidiary, CarieScan Limited (“CarieScan”), is a leading producer of handheld devices for the early detection and monitoring of tooth decay, is pleased to announce that it has received 510(k) clearance from the Food & Drug Administration (“FDA”), allowing the CarieScan PROtm to be marketed in the United States of America (“US”).This is a key milestone for CarieScan which opens up the major diagnostic market in the US to CarieScan PROtm,, providing a basis for securing a US distribution partner, giving the Company the opportunity to significantly increase product sales.The CarieScan PROtm measures the presence of tooth decay earlier

More...